Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization.

Carla A Lawendowski1, Gina M Giurleo, Yin Yin Huang

  • 1Genzyme Molecular Oncology, Framingham, MA 01701, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|August 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between efficacy and preferential targeting of soluble Aβ aggregates.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Profiling cells with DELs: Small molecule fingerprinting of cell surfaces.

SLAS discovery : advancing life sciences R & D·2024
Same author

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.

Acta neuropathologica communications·2023
Same author

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma.

Human vaccines & immunotherapeutics·2023
Same author

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein.

Biomedicines·2022
Same journal

Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Increased Nur77 is disconnected from TCR affinity in insulin-specific Tregs.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

FTR85 negatively regulates type I IFN antiviral signaling pathway by promoting K48-linked polyubiquitination of IRF3.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

An MR1-specific nanobody capable of blocking MR1T cell activation.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

TGF-β controls developmental fate and functional identity of thymic γδ T cells.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Distinguishing Th17 cells as a unique subset.

Journal of immunology (Baltimore, Md. : 1950)·2026
See all related articles

Researchers developed a new method to identify potent cancer immunotherapy peptides. This approach screens numerous peptide variants to find those that effectively activate T cells against cancer, overcoming self-tolerance issues.

Area of Science:

  • Immunology
  • Cancer Research
  • Vaccine Development

Background:

  • Self-tolerance to nonmutated antigens presents a major obstacle in cancer immunotherapy.
  • Altered peptide ligands (APLs) show potential for enhanced immunogenicity over native epitopes, but prediction remains challenging.

Purpose of the Study:

  • To develop an empirical screening method for identifying APLs with enhanced immunogenic properties.
  • To overcome the limitations in predicting which peptide modifications elicit superior immune responses.

Main Methods:

  • Solid-phase epitope recovery (SPER) was employed to rapidly assay a combinatorial spectrum of peptides.
  • SPER quantitatively ranks reactive peptides, enabling selection of APLs with desirable immunogenic traits.
  • Identified peptides were highly substituted in predicted T cell receptor (TCR) contact residues.

Related Experiment Videos

Main Results:

  • SPER-identified peptides reliably activated and expanded effector T cell populations in vitro.
  • These peptides induced lysis of target cells presenting the wild-type epitope.
  • Peptides targeting the melanoma antigen gp100 reliably induced wild-type peptide-specific cytotoxic T lymphocytes (CTLs) in normal donor T cells.
  • Combinations of these peptides induced robust CTL responses in a majority of individuals tested in vitro.

Conclusions:

  • SPER provides a reliable method for discovering potent APLs for cancer immunotherapy.
  • The identified APLs can overcome self-tolerance and induce specific CTL responses.
  • These findings support the design of novel vaccines using mixtures of structurally diverse, functionally convergent peptides.